153 related articles for article (PubMed ID: 7645927)
1. Clinical utility of tissue polypeptide antigen determination in lung cancer management.
Rapellino M; Pecchio F; Baldi S; Scappaticci E; Cavallo A
Anticancer Res; 1995; 15(3):1065-70. PubMed ID: 7645927
[TBL] [Abstract][Full Text] [Related]
2. Tissue polypeptide antigen in bronchogenic carcinoma.
Zatloukal P; Glagolicová A; Linhart M; Sebes A; Hencl P; Mĕricka O
Neoplasma; 1993; 40(5):301-3. PubMed ID: 8272159
[TBL] [Abstract][Full Text] [Related]
3. [Trials of the diagnostic potentials of TPA in tumorous and nontumorous lung pathologies in 303 cases].
Aquilina R; Bergero F; Magri G; Noceti P; Mirabelli S
Minerva Med; 1992; 83(7-8):415-9. PubMed ID: 1522964
[TBL] [Abstract][Full Text] [Related]
4. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
Pan QR; Zhang X; Xu ZF; Zheng S
Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
[TBL] [Abstract][Full Text] [Related]
5. [Importance of serum TPA determination in bronchopulmonary cancer. A comparative study of CEA, CA 19.9 and NSE].
Prévost A; Passemard F; Perdu D; Vallerand H; Deschamps F; Lavaud F; Larbre H
Rev Mal Respir; 1994; 11(4):379-84. PubMed ID: 7973038
[TBL] [Abstract][Full Text] [Related]
6. [Tumor markers in the diagnosis and follow-up assessment of bronchial carcinoma].
Fischbach W
Dtsch Med Wochenschr; 1989 May; 114(20):800-5. PubMed ID: 2656177
[No Abstract] [Full Text] [Related]
7. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
Ebert W; Muley T; Drings P
Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
[TBL] [Abstract][Full Text] [Related]
8. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer.
Buccheri G; Ferrigno D
J Thorac Cardiovasc Surg; 2001 Nov; 122(5):891-9. PubMed ID: 11689793
[TBL] [Abstract][Full Text] [Related]
9. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
[TBL] [Abstract][Full Text] [Related]
11. Serum tissue polypeptide antigen (TPA) as tumor marker for bladder cancer.
van Poppel H; Billen J; Goethuys H; Elgamal AA; Gerits M; Mortelmans L; Blanckaert N; Baert L
Anticancer Res; 1996; 16(4B):2205-7. PubMed ID: 8694544
[TBL] [Abstract][Full Text] [Related]
12. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
[TBL] [Abstract][Full Text] [Related]
13. [Role of tissue polypeptide antigen as a marker in bladder cancer].
Menéndez V; Filella X; Alcover J; Molina R; Ballesta AM; Carretero P
Actas Urol Esp; 1995 Jun; 19(6):441-4. PubMed ID: 8571803
[TBL] [Abstract][Full Text] [Related]
14. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
15. Lung cancer. An update.
Matthews JI; Blanton HM
Prim Care; 1985 Jun; 12(2):267-81. PubMed ID: 3848021
[TBL] [Abstract][Full Text] [Related]
16. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma.
Nagler RM; Barak M; Peled M; Ben-Aryeh H; Filatov M; Laufer D
Cancer; 1999 Mar; 85(5):1018-25. PubMed ID: 10091783
[TBL] [Abstract][Full Text] [Related]
17. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
[TBL] [Abstract][Full Text] [Related]
18. Treatment of bronchogenic carcinoma with surgery and radiotherapy: the experience of the National Cancer Institute of Milan.
Bucalossi P; Ravasi G; Bozzetti F; Milani F
Cancer Chemother Rep 3; 1973 Mar; 4(2):101-7. PubMed ID: 4729313
[No Abstract] [Full Text] [Related]
19. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
[TBL] [Abstract][Full Text] [Related]
20. [Measurement of serum tissue polypeptide antigen (TPA) in patients with malignant tumor using prolifigen TPA-M "Daiichi" kit].
Sakahara H; Endo K; Torizuka K; Itoh K; Ohuchi N; Inaba N; Miyaji Y; Takayama M; Ishii K; Takagi H; Konishi J; Fukuoka M; Fukuchi M; Ohkawa J; Kagawa S; Kondo S; Shirouzu K; Iguchi H
Gan To Kagaku Ryoho; 1996 May; 23(6):733-43. PubMed ID: 8645025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]